Opportunities and challenges of natural killer cell-derived extracellular vesicles

Abstract

Extracellular vesicles (EVs) are increasingly recognized as important intermediaries of intercellular communication. They have significant roles in many physiological and pathological processes and show great promise as novel biomarkers of disease, therapeutic agents, and drug delivery tools. Existing studies have shown that natural killer cell-derived EVs (NEVs) can directly kill tumor cells and participate in the crosstalk of immune cells in the tumor microenvironment. NEVs own identical cytotoxic proteins, cytotoxic receptors, and cytokines as NK cells, which is the biological basis for their application in antitumor therapy. The nanoscale size and natural targeting property of NEVs enable precisely killing tumor cells. Moreover, endowing NEVs with a variety of fascinating capabilities via common engineering strategies has become a crucial direction for future research. Thus, here we provide a brief overview of the characteristics and physiological functions of the various types of NEVs, focusing on their production, isolation, functional characterization, and engineering strategies for their promising application as a cell-free modality for tumor immunotherapy.

1 Introduction

Cancer immunotherapy has gained widespread attention as a clinically proven therapeutic strategy, and the relay transfer of natural killer (NK) cells has emerged as a promising approach to controlling the immune system against cancer. As the first line of defense against tumors and viral infections, NK cells can induce antigen-independent immune responses against malignant cells. A growing number of scientific reports and clinical studies have demonstrated that NK cell-based immunotherapy has promising antitumor effects (Laskowski et al., 2022). Furthermore, NK cell therapy or chimeric antigen receptor (CAR) NK cell therapy has unique advantages over existing hot T-cell immunotherapy (Biederstadt and Rezvani, 2021; Rafei et al., 2021). NK cells recognize and kill tumors by combining signals generated by independent inhibitory and activating receptors, effectively inhibiting tumor escape through antigen downregulation (Basar et al., 2020). Currently, a wide spectrum of research is being conducted on NK cell-related cancer therapies, including CAR NK, engineered NK cells, and allogeneic natural killer cell infusion (Tang et al., 2018; Liu et al., 2021). However, despite several clinical trials, the prospects for NK cell-based therapies for solid tumors are not optimistic. Challenges include difficulty in ex vivo expansion meeting clinical grade, tumor immune escape, limited in vivo persistence, and limited infiltration into solid tumors (Oh et al., 2019; Bald et al., 2020). Moreover, the tumor microenvironment (TME) inhibits NK cell responses (Fang et al., 2018; Lian et al., 2021). These factors directly hinder or limit the use of NK cells in solid tumor therapy.

Extracellular vesicles (EVs) can be divided into three subgroups based on their biological origin, including exosomes (30–150 nm in diameter), microvesicles (150–1,000 nm), and apoptotic vesicles (50–2,000 nm). The role of EVs secreted by immune cells in antitumor therapy has received more attention in recent years, with many studies confirming their great potential (Shen and Ren, 2018; Choi et al., 2022a). Among them, NK cell-derived EVs (NEVs) have gained more attention for their unique biological properties. NEVs possess NK cell surface receptors and cytotoxic proteins that function similarly to parental cells, enabling them to kill tumors directly in the TME. Unlike cells, nanoscale NEVs can easily diffuse and infiltrate solid tumors and own natural targeting and biocompatibility properties. Furthermore, there have been few types of research showing that immunosuppressive TME affects NEVs. Therefore, the emergence of NEVs may overcome the limitations of NK cells in immunotherapy. Numerous studies have thoroughly investigated the biological basis for tumor killing by NEVs and found that they carry a variety of bioactive molecules, including membrane toxicity receptors, cytotoxic proteins, cytokines, and microRNAs (miRNAs). This is the biological basis for NEVs natural tumor-killing and tumor-targeting properties, as well as the ability to interact with immune cells such as tumor-associated macrophages (TAM) and cytotoxic T lymphocyte (CTL) (Federici et al., 2020). Due to the above advantages, engineered NEVs have received a lot of attention to enhance their tumor-killing capabilities. Current research focuses on the use of engineered modifications to enhance the functionality of NEVs (Yang et al., 2021a). Nevertheless, many challenges remain in the development of NEVs, such as cell source production methods and interaction mechanisms. This review aims to summarize the latest research on the production, application, mechanism, and modification of NEVs (Figure 1).

FIGURE 1

2 Preparation of NEVs

2.1 NK cell source

For both NK cells and NEVs used in therapeutic studies, the optimal source of NK cells is currently a controversial topic. Peripheral blood mononuclear cells (PBMC) and cell lines are the two main sources of NK cells used in therapeutic studies. PBMC can be obtained from patient blood or blood collected from healthy adult volunteers. Among them, PBMC-induced NK cells from cancer patients had fewer clinical adverse effects and a higher safety profile (Sakamoto et al., 2015; Fang et al., 2018; Fang et al., 2022). However, their cytotoxic properties are compromised, with significantly reduced expression of activating receptors such as NKG2D, DNAM-1, and NKp46, which directly affects their derived EVs (Cianga et al., 2021). In contrast, healthy population-derived allogeneic NK cells have high yield and cytotoxicity but a low safety profile (Federici et al., 2020). It is worth noting that PBMC-derived NK cells are difficult to use in tumor therapy on a large scale and for a long time due to the restriction of donor and blood groups (Shah et al., 2015). Another important source is NK cell lines, such as NK-92 or NK-92MI, are important sources of NK cells and have become one of the important alternatives to autologous NK cell biologics. Moreover, the NK-92 cell line is the only human NK cell line approved for clinical use by the FDA. NK-92 can be expanded in culture in the presence of cytokines (NK-92MI amplification in vitro is not cytokine-dependent). It is inexpensive to administer, and there is substantial evidence that it is relatively safe (Gong et al., 1994). A study comparing the distribution of cytolytic proteins in NEVs from primary NK and NK-92 cells and found strong similarities and the same satisfactory tumor-killing effect (Aarsund et al., 2022).

Furthermore, umbilical cord blood (UCB), hematopoietic stem and progenitor cells (HSPCs), induced pluripotent stem cells (iPSCs), and CAR NK cells are valuable sources of NK cells (Li et al., 2018; Kundu et al., 2021; Boyd-Gibbins et al., 2022). CAR-NK and iPSC-NK cells could benefit from advances in manufacturing and genome engineering techniques to create NK cells and NEVs with context-dependent functions and enhanced potency and specificity. Future research is required to confirm the differences in the composition and effects of EVs produced by NK cells from different sources. The common cellular sources of NEVs production and their advantages and disadvantages are summarized in Table 1.

2.2 Production of NEVs

The most common method for isolating EVs is cell culture supernatant collection. Since there is no “gold standard protocol” for the preparation of pure EVs, the properties and functions of EVs may vary depending on the culture and isolation methods. Differences in cell culture oxygen content and inoculation surface have been shown to affect EVs production (Zhang et al., 2017; Liu et al., 2020). Differences in cultural media also have an impact on EVs extraction. It has been shown that exogenous proteins introduced into cell culture can affect the type and characteristics of exosomes (Whitford and Guterstam, 2019; Chen et al., 2020). However, it has also been shown that the emergence of serum-free media modifies the biology of EVs (Mendt et al., 2018).

Obtaining EVs through natural secretion is hampered by the low yield. The advent of exosome-mimetic vesicles (EMs) with higher yield is expected to resolve this issue (Ou et al., 2021). Large-scale production of EMs could be an alternative to conventional EVs production. When cytoplasmic membranes are forced to rupture, they reassemble into smaller vesicles. Thus, EMs with diverse sizes can be produced using diverse filter membranes and micro-extruders. A study reported that the production of EMs using this method was 250 times higher than naturally secreted EVs (Lee et al., 2020). More recently, similar methods have been used to produce NK EMs, with tumor-killing abilities and impressive stability under physiological conditions, which could also be loaded with chemotherapeutic drugs for targeted cancer therapy (Pitchaimani et al., 2018; Zhu et al., 2018). However, more research is needed to investigate the differences in efficacy and safety with naturally secreted EVs.

Either artificially generated EMs or naturally secreted EVs typically contain multiple types of biological impurities. Therefore, it is essential to ensure that the purified products are inherently EVs without other contaminants before performing any functional analysis of the EVs. The current EVs isolation and purification methods and their advantages and disadvantages are summarized in Table 2.

2.3 Storage of NEVs

As a promising cell-free therapy, achieving long-term and stable storage of NEVs plays a key role in their clinical application. Therefore, it is necessary to explore preservation techniques to protect the biological activity of NEVs for transport and clinical applications. Common conservation techniques include freezing, lyophilization, and spray drying (Kusuma et al., 2018; Charoenviriyakul et al., 2019; Zhang et al., 2020a). Any frozen storage may “frostbite” the EVs, and the use of antifreeze may extend their shelf life. The traditional approach of adding DMSO during cryopreservation can protect the biological activity of EVs (Wu et al., 2015). Furthermore, alginate is considered as the most effective disaccharide antifreeze agent and prevents EVs aggregation and increases its stability without changing EVs morphology (Bosch et al., 2016; Charoenviriyakul et al., 2018). A recent study reported that PBS supplemented with human albumin and trehalose buffer significantly improved the short and long-term preservation of EVs samples stored at −80°C, and maintained stability over multiple freeze-thaw cycles (Gorgens et al., 2022). Moreover, the storage of EVs also varies from different sources and modifications (Agrawal et al., 2017). Multiple studies on NEVs have analyzed the impact of storage on NEVs and concluded that the existing technology could effectively ensure the storage stability of NEVs (Jong et al., 2017; Farcas and Inngjerdingen, 2020). In summary, the rational use of various EVs storage methods can significantly improve the storage stability of EVs and provide greater application benefits.

3 Function mechanisms of NEVs

In recent years, as research on NEVs have continued, knowledge about the mechanisms underlying their function has been gained. Several studies have confirmed the ability of NEVs to target and kill tumor cells, which have been summarized in Table 3. This section highlights the characteristics and mechanisms of the currently known NEVs in oncology therapy.

3.1 NEVs exert antitumor effects through their contents and membrane proteins

NEVs contain many substances acting as tumor killers, such as membrane proteins, toxic proteins, and miRNAs. In this section, we will elaborate on each section individually (as shown in Figure 2).

FIGURE 2

Several studies have shown that NEVs can express NK cell surface receptors (Zhu et al., 2019; Choi et al., 2020). These receptors include Natural Killer Lytic-Associated Molecule (NKLAM), Fas-L, DNAX accessory molecules-1 (DNAM-1/CD226), and NKG2D (CD314) (Enomoto et al., 2021). The expression of the natural cytotoxic receptor (NCR), NKp44 (CD336), NKp30 (CD337), NKp46 (CD335), and CD16 varies according to cell sources and activation status (Lugini et al., 2012). Moreover, NEVs induce apoptosis through a classical ligand/receptor interaction between Fas-L on the membrane surface and Fas on the target cell membrane. Fas-L binding to the membrane receptor results in the formation of the death-inducing signaling complex (DISC), which activates the extrinsic apoptotic pathway by activating the caspase pathway (Lavrik and Krammer, 2012; Sparrow and Bodman-Smith, 2020). The CD47 expressing on the NEVs surface interacts with its receptor on macrophages, SIRP-α, to inhibit the elimination of NEVs by macrophage via phagocytosis, thus enabling longer cycle times (Jaiswal et al., 2009; Wang et al., 2019).

Perforin, granzyme A, B, granulysin, and tumor necrosis factor α (TNF-α) are all found in NEVs (Korenevskii et al., 2018; Cochran and Kornbluth, 2021). The perforin in NEVs can penetrate the cell membrane and allow cytotoxic proteins (granzyme A, B, granulysin) to enter the target cell and induce apoptosis by disrupting the outer mitochondrial membrane potential and cleaving caspases (Leon et al., 2017; Wu et al., 2019). Among them, granzyme B targets and cleaves cystathionine-3 and -7 directly, leading to the rapid initiation of apoptosis. It also induces an intrinsic apoptotic pathway by cleaving Bid to tBid (BH3 interacting domain death agonist protein), which disrupts the outer mitochondrial membrane potential and releases cytochrome C (MacDonald et al., 1999). The specific target of granzyme A in the apoptotic pathway is the SET complex, an ER-associated complex whose cleavage causes single-stranded DNA damage (Lieberman, 2010). Granulysin can induce apoptosis by binding to target cell membranes through electrostatic interactions based on its positive N-terminal charge. This process can disrupt cell membranes, active Caspase-9, and Caspase-12 by damaging mitochondria, as well as damaging the endoplasmic reticulum and activating Caspase-7 (Sparrow and Bodman-Smith, 2020). One quantitative analysis study demonstrated that NK-92 EVs revealed higher levels of perforin and Fas-L than NK cells and performed more effective inhibition of tumor proliferation (Zhu et al., 2017).

Regulatory miRNAs found in NEVs demonstrate tumor-killing and immunomodulation ability. Among these, miR-3607-3p encapsulated in NEVs inhibits cancer cell migration and invasion; miR-3607-3p-enriched NEVs may inhibit the malignant transformation of pancreatic cancer by directly targeting IL-26, and decreased miR-3607-3p levels were associated with poor prognosis and tumor metastasis (Sun et al., 2019). Another study demonstrated that miR-186-5p in NEVs can inhibit the growth and spread of neuroblastoma and induce apoptosis, and miR-186-5p containing NEVs was also taken up by NK cells to reduce the inhibition of cytotoxicity by the TME (Neviani et al., 2019). A recent study suggests that miR-10b-5p, miR-92a-3p, and miR-155-5p found in NEVs play a crucial role in immune regulation (Dosil et al., 2022). In addition, more information was summarized in Table 4.

3.2 Immunomodulatory effects of NEVs

EVs secreted by numerous immune cells can be used to regulate innate and acquired immune responses (Lugini et al., 2012; Hong and Kim, 2022). NEVs possess similar immunomodulatory functions in the immune system (Figure 2). On the one hand, NEVs can effectively reduce the number of pre-tumor M2 macrophages or induce tumor-killing M1 macrophage polarization, which attenuates TAM-mediated CTL inhibition via the change of TAM -secreted cytokines and membrane surface proteins, and induces a direct antitumor effect of M1 macrophage (Bellora et al., 2014; Jia et al., 2020; Nie et al., 2021). NEVs can also act directly on T-cell activation or indirectly by stimulating monocytes to positively influence T-cell activation (Figures 3A–E) (Federici et al., 2020). Analyzing the miRNA types in NEVs reveals that they promote T-cell activation and induce DC expression of MHC-II and CD86 (Dosil et al., 2022). Furthermore, NEVs contribute to NK cell activation. A study demonstrated that NEVs pre-exposed to tumor cells could activate resting NK cells in humans, leading to higher levels of NCR and acquiring greater tumor-killing capacity (Figures 3F–H) (Shoae-Hassani et al., 2017). However, the immunomodulatory function of NEVs is still unknown due to the lack of in-depth mechanistic studies.

FIGURE 3

4 Characteristics of NEVs for therapeutic

4.1 Penetration

The TME and biological barrier, which are difficult to overcome in traditional tumor therapy, are important reasons that affect the therapeutic effect. NEV has a smaller molecular diameter and greater tissue penetration into solid tumors compared to whole cells. For example, the small molecular size of NEVs allows them to easily cross the blood-brain barrier (BBB) and enter the cancer reservoir to kill or deliver the drugs to central nervous system (CNS) tumors (Neviani et al., 2019; Weng et al., 2021; Choi et al., 2022b).

4.2 Natural targeting

Multiple studies have confirmed the ability of NEVs to target tumors (Lugini et al., 2012; Zhu et al., 2019; Sayitoglu et al., 2020). This characteristic may be attributed to the membrane proteins CXC receptors (CXCR3 and CXCR4), NCR, NKG2D, and DNAM-1 on the surface of NEVs, which can induce cancer cell lysis while targeting tumor cells (Deng et al., 2018; Wang et al., 2019; Di Pace et al., 2020; Sayitoglu et al., 2020; Aarsund et al., 2022). However, there is still some controversy about the targeting mechanism of NEVs.

4.3 Biocompatibility

NEVs enter target cells through micropinocytosis, and the number of internalized NEVs correlates with tumor cell cytotoxicity (Azarmi et al., 2020; Di Pace et al., 2020; Enomoto et al., 2021). It was discovered that co-incubating NEVs with target cells for approximately 30 min resulted in detection in target cells and induced maximal cytotoxic effects after 8–14 h (Zhu et al., 2017; Di Pace et al., 2020). Furthermore, it has been demonstrated that the acidic tumor microenvironment promotes the uptake of NEVs by tumor cells (Parolini et al., 2009; Fais, 2013).

4.4 Security

All current NEVs research has addressed the safety of NEVs at the cellular or animal level. Some studies point out that NEVs derived from PBMC have cytolytic activity against cancer cells but not against normal resting PBMC cells or normal cells (Lugini et al., 2012; Groot Kormelink et al., 2018). Furthermore, numerous studies have concluded that NEVs do not pose serious safety concerns in animal studies (Han et al., 2020; Kaban et al., 2021; Zhang et al., 2022). Existing research can provide initial confirmation of the safety of NEVs. However, because most of them are in vitro experiments, safety issues will become an issue that has to be addressed for the future development of NEVs.

4.5 Adjustability

EVs-secreting behavior of NK cells is independent of cell activation status (Fais, 2013; Aarsund et al., 2022). However, the killing activity of NEVs is closely related to the state of cell activation (Lugini et al., 2012). This process is regulated by many factors; for example, NEVs exhibited stronger cytotoxic effects and elevated levels of cytotoxicity-related molecules in hypoxic environments (Jiang et al., 2021). NEVs pre-exposed to the tumor environment may have higher cytotoxicity (Shoae-Hassani et al., 2017). Furthermore, the cytotoxicity of NEVs can be modulated by various cytokines (Markova et al., 2021; Aarsund et al., 2022). Namely, higher quality NEVs would be produced by appropriate regulation of NK cells based on the above characteristics in the future.

5 Engineering strategy for NEVs

Endowing EVs with a variety of fascinating capabilities via common engineering strategies has become a crucial direction for much applied research. Common EVs engineering techniques can be classified as endogenous and exogenous modifications. The primary objective is to increase the targeting ability or transform them into drug carriers (Gudbergsson et al., 2019; Zhang et al., 2020b). Existing engineering studies of NEVs are few but have shown satisfactory results.

5.1 Exogenous modifications

NEVs are suitable for drug delivery systems (DDS) due to their strong penetration, antitumor activity, and natural targeting. The current strategy is transporting exogenous drugs into NEVs, with engineering methods mainly including electroporation, ultrasonication, extrusion, freeze-thaw cycles, and saponin treatment (Thakur et al., 2022). NEVs were used in a study to enhance the antitumor effects of the drug by encapsulating paclitaxel via electroporation (Figure 1A) (Han et al., 2020). Another study reported that NEVs loaded with doxorubicin by ultrasonication demonstrated excellent antitumor activity against MCF-7 human breast cancer cells both in vitro and in vivo (Figure 1B) (Pitchaimani et al., 2018). A recent study using NEVs loaded with hydrophilic siRNA and the hydrophobic photosensitizer Ce6 showed obvious tumor-killing effects due to not only the anti-tumor property of the NEVs but also the combination of the powerful gene silencing effect by the delivery of siRNA and significant photodynamic therapeutic effects with reactive oxygen species (ROS) generated after laser irradiation (Figures 1C, 4A) (Zhang et al., 2022). The use of NEVs in drug delivery overcomes most of the drawbacks of conventional nanomaterial drug delivery systems.

FIGURE 4

Surface engineering is another type of exogenous modification of interest. Surface engineering of NEVs can improve their targeting or binding to other substances, increasing their stability and duration of action in vivo. Introducing nanomaterials and inserting lipophilic components into the membrane by fusion with liposomes or adsorbing molecules is the main approach for the surface engineering of NEVs (Yang et al., 2021a). The linkage can also be formed through covalent bonds on the vesicle surface through azide-alkyne cycloaddition reactions (Richter et al., 2021). In a recent study, NEVs were modified with dibenzocyclooctynes (DBCO), and CTL was modified with azide groups, respectively, which were subsequently linked via biorthogonal chemistry. Due to the pH-responsive structure, the NEVs could be released at low PH, exploiting their ability to target tumors during circulation and promote CTL to kill tumors (Figures 1D, 4B) (Nie et al., 2021). Another study reported using cocktail therapy by combining NEVs with dendrimer core loaded with therapeutic miRNAs for tumor-targeted therapy (Figures 1E, 4C) (Wang et al., 2019).

5.2 Endogenous modifications

Endogenous modification is also an essential method for the functionalization of NEVs. It is intended to engineer the membrane and contents of NEVs by genetically modifying the parent cells expressing the specific target product or chimeric protein. A genetic engineering study of the NK-92MI using lentiviral transduction to express BCL-2 siRNA (siBCL-2), which is enriched in NEVs and successfully enhanced tumor-killing ability by inhibiting overexpression of BCL-2 in breast cancer (Figures 1F, 4D) (Kaban et al., 2021). A study reported that EVs isolated from mesothelin-targeted CAR-T cells maintained most of the parental cells’ characteristics and had the same therapeutic potential without significant side effects (Yang et al., 2021b). Moreover, the administration of CAR cell-derived EVs is relatively safer than CAR cell therapy (Fu et al., 2019). However, there still exists no detailed study using CAR NK-derived EVs. Take as a whole, genetic engineering enables good control over the generated EVs; once the corresponding cell line is established, no further work is required to generate the modified EVs, making it an ideal method for the mass production of engineered EVs in the future.

6 Discussion

This review highlights the challenges and potential of NEVs in cancer therapy, which has demonstrated tremendous advantages in recent years as an emerging cell-free therapy in cancer immunotherapy, including smaller size, greater tissue penetration, lower acquisition costs, and independence from inhibitory TAM compared to conventional NK cell therapies. The NEVs inherit the tumor-killing and natural targeting abilities of their parent cells. It is associated with relatively few immune side effects due to the absence of cellular involvement. Therefore, in addition to cell therapy, NEVs have the potential to play a crucial role in future tumor immunotherapy.

The role of NEVs is still poorly understood, and researchers continue to investigate it. One study showed that NK-92MI cells-derived EVs could inhibit TGF-β1-induced HSC proliferation and activation, preventing liver fibrosis by carrying miR-223 (Wang et al., 2020a; Wang et al., 2020b). Another study demonstrated that miR-207-containing NEVs alleviated symptoms of chronic mild stress in mice, suggesting that NEVs may also have a role in the treatment of depression (Wang et al., 2020a; Wang et al., 2020b). Moreover, NEVs ameliorated lung injury in a mouse model of Pseudomonas aeruginosa lung infection by promoting M1 macrophage polarization. This suggests that NEVs may play a protective role in inflammation, especially in diseases with an imbalanced M1/M2 macrophage ratio (69). As the in-depth functions of NEVs have not yet be investigated, following research may need to focus on the functional contained biomolecules and the critical roles in the immune regulation process.

Despite the large number of studies demonstrating the efficacy of NEVs in cancer therapy, the development of NEVs still faces significant challenges. Not only do NEVs face these challenges, but all therapeutic EVs developments must also overcome them. The first is the heterogeneity of EVs, which complicates quality control and hinders a comprehensive understanding of their function. The main reason comes from the cell source and isolation methods for the production of EVs. The optimal cell source and isolation method for EVs is still under investigation. Ultracentrifugation is the most widely-used EVs isolation method, which needs to be integrated with another isolation method to improve the separation purity. The second challenge is selecting designs that improve the cycling stability and the cytotoxicity of NEVs. As mentioned above, although various endogenous and exogenous modification methods are used, there is no effective method to improve the loading efficiency of bioactive molecules without compromising the integrity of EVs, and most modification methods may cause clustering. Furthermore, it is necessary to evaluate the need for these modifications and their improvement in therapeutic efficacy. A reliable method to determine whether the loaded EVs contain active molecules is still urgently needed (Wahlgren et al., 2012). Finally, due to the insufficient number of studies and inconsistent experimental conditions, there is no uniform standard on how numerous NEVs and how long it will take to achieve the desired anticancer effect, as well as what delivery method and treatment regimen should be employed during treatment to achieve improved clinical outcomes. Therefore, there is still much work to be done before the utilization of NEVs in clinical settings. Although the full-scale mechanism and function of NEVs need to be addressed, NEVs are a highly promising cell-free therapeutic option, which are easily to be obtained, modified, and stored in comparison with cells. The increasing number of studies on engineering NEVs have also proved it as an excellent vector for personalized modification. The unique anti-tumor properties of NEVs convince us that the anti-tumor strategy based on NEVs is worthy of comprehensive and in-depth study. Future research should take full advantage of NEVs and integrate it with multiple therapeutic strategies including sonodynamic therapy, photodynamic therapy, photothermal therapy and radiotherapy, so as to achieve more powerful tumor-killing effects. We hope this review will contribute to the promotion of multidisciplinary research on NEVs in a concerted effort to make NEVs the next-generation of cancer therapeutic strategy.

References

• 1

  Aarsund M. Segers F. M. Wu Y. Inngjerdingen M. (2022). Comparison of characteristics and tumor targeting properties of extracellular vesicles derived from primary nk cells or nk-cell lines stimulated with il-15 or il-12/15/18. Cancer Immunology Immunotherapy.71 (9), 2227-2238. 10.1007/s00262-022-03161-0

  • CrossRef
  • Google Scholar

• 2

  Agrawal A. K. Aqil F. Jeyabalan J. Spencer W. A. Beck J. Gachuki B. W. et al (2017). Milk-derived exosomes for oral delivery of paclitaxel. Nanomedicine13 (5), 1627–1636. Epub 2017/03/17. 10.1016/j.nano.2017.03.001

  • CrossRef
  • Google Scholar

• 3

  Azarmi M. Maleki H. Nikkam N. Malekinejad H. (2020). Transcellular brain drug delivery: A review on recent advancements. Int. J. Pharm.586, 119582. Epub 2020/07/01. 10.1016/j.ijpharm.2020.119582

  • CrossRef
  • Google Scholar

• 4

  Bald T. Krummel M. F. Smyth M. J. Barry K. C. (2020). The nk cell-cancer cycle: Advances and new challenges in nk cell-based immunotherapies. Nat. Immunol.21 (8), 835–847. Epub 2020/07/22. 10.1038/s41590-020-0728-z

  • CrossRef
  • Google Scholar

• 5

  Basar R. Daher M. Rezvani K. (2020). Next-generation cell therapies: The emerging role of car-nk cells. Hematol. Am. Soc. Hematol. Educ. Program2020 (1), 570–578. Epub 2020/12/05. 10.1182/hematology.2020002547

  • CrossRef
  • Google Scholar

• 6

  Bellora F. Castriconi R. Dondero A. Carrega P. Mantovani A. Ferlazzo G. et al (2014). Human nk cells and nk receptors. Immunol. Lett.161 (2), 168–173. Epub 2013/12/24. 10.1016/j.imlet.2013.12.009

  • CrossRef
  • Google Scholar

• 7

  Biederstadt A. Rezvani K. (2021). Engineering the next generation of car-nk immunotherapies. Int. J. Hematol.114 (5), 554–571. Epub 2021/08/29. 10.1007/s12185-021-03209-4

  • CrossRef
  • Google Scholar

• 8

  Bosch S. de Beaurepaire L. Allard M. Mosser M. Heichette C. Chretien D. et al (2016). Trehalose prevents aggregation of exosomes and cryodamage. Sci. Rep.6, 36162. Epub 2016/11/09. 10.1038/srep36162

  • CrossRef
  • Google Scholar

• 9

  Boyd-Gibbins N. Karagiannis P. Hwang D. W. Kim S. I. (2022). Ipscs in nk cell manufacturing and nkev development. Front. Immunol.13, 890894. Epub 2022/07/26. 10.3389/fimmu.2022.890894

  • CrossRef
  • Google Scholar

• 10

  Charoenviriyakul C. Takahashi Y. Nishikawa M. Takakura Y. (2019). Erratum to ‘Preservation of exosomes at room temperature using lyophilization. Int. J. Pharm.559, 427–428. Epub 2019/03/02. 10.1016/j.ijpharm.2019.02.037

  • CrossRef
  • Google Scholar

• 11

  Charoenviriyakul C. Takahashi Y. Nishikawa M. Takakura Y. (2018). Preservation of exosomes at room temperature using lyophilization. Int. J. Pharm.553 (1-2), 1–7. Epub 2018/10/15. 10.1016/j.ijpharm.2018.10.032

  • CrossRef
  • Google Scholar

• 12

  Chen Y. S. Lin E. Y. Chiou T. W. Harn H. J. (2020). Exosomes in clinical trial and their production in compliance with good manufacturing practice. Ci Ji Yi Xue Za Zhi32 (2), 113–120. Epub 2020/04/10. 10.4103/tcmj.tcmj_182_19

  • CrossRef
  • Google Scholar

• 13

  Choi H. Choi K. Kim D. H. Oh B. K. Yim H. Jo S. et al (2022). Strategies for targeted delivery of exosomes to the brain: Advantages and challenges. Pharmaceutics14 (3), 672. Epub 2022/03/27. 10.3390/pharmaceutics14030672

  • CrossRef
  • Google Scholar

• 14

  Choi J-W. Lim S. Kang J. H. Hwang S. H. Hwang K-C. Kim S. W. et al (2020). Proteome analysis of human natural killer cell derived extracellular vesicles for identification of anticancer effectors. Molecules25 (21), 5216. 10.3390/molecules25215216

  • CrossRef
  • Google Scholar

• 15

  Choi S-J. Cho H. Yea K. Baek M-C. (2022). Immune cell-derived small extracellular vesicles in cancer treatment. Bmb Rep.55 (1), 48–56. 10.5483/BMBRep.2022.55.1.133

  • CrossRef
  • Google Scholar

• 16

  Cianga V. A. Campos Catafal L. Cianga P. Pavel Tanasa M. Cherry M. Collet P. et al (2021). Natural killer cell subpopulations and inhibitory receptor dynamics in myelodysplastic syndromes and acute myeloid leukemia. Front. Immunol.12, 665541. Epub 2021/05/15. 10.3389/fimmu.2021.665541

  • CrossRef
  • Google Scholar

• 17

  Cochran A. M. Kornbluth J. (2021). Extracellular vesicles from the human natural killer cell line Nk3.3 have broad and potent anti-tumor activity. Front. Cell Dev. Biol.9, 698639. 10.3389/fcell.2021.698639

  • CrossRef
  • Google Scholar

• 18

  Coughlan C. Bruce K. D. Burgy O. Boyd T. D. Michel C. R. Garcia-Perez J. E. et al (2020). Exosome isolation by ultracentrifugation and precipitation and techniques for downstream analyses. Curr. Protoc. Cell Biol.88 (1), e110. Epub 2020/07/08. 10.1002/cpcb.110

  • CrossRef
  • Google Scholar

• 19

  Deng G. Sun Z. Li S. Peng X. Li W. Zhou L. et al (2018). Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano12 (12), 12096–12108. Epub 2018/11/18. 10.1021/acsnano.8b05292

  • CrossRef
  • Google Scholar

• 20

  Di Pace A. L. Tumino N. Besi F. Alicata C. Conti L. A. Munari E. et al (2020). Characterization of human nk cell-derived exosomes: Role of Dnam1 receptor in exosome-mediated cytotoxicity against tumor. Cancers (Basel)12 (3), 661. Epub 2020/03/18. 10.3390/cancers12030661

  • CrossRef
  • Google Scholar

• 21

  Dosil S. G. Lopez-Cobo S. Rodriguez-Galan A. Fernandez-Delgado I. Ramirez-Huesca M. Milan-Rois P. et al (2022). Natural killer (nk) cell-derived extracellular-vesicle shuttled micrornas control T cell responses. Elife, 11, e76319Epub 2022/07/30. 10.7554/eLife.76319

  • CrossRef
  • Google Scholar

• 22

  Enomoto Y. Li P. Jenkins L. M. Anastasakis D. Lyons G. C. Hafner M. et al (2021). Cytokine-enhanced cytolytic activity of exosomes from nk cells. Cancer Gene Therapy. 29, 734, 10.1038/s41417-021-00352-2

  • CrossRef
  • Google Scholar

• 23

  Fais S. (2013). Nk cell-released exosomes: Natural nanobullets against tumors. Oncoimmunology2 (1), e22337. Epub 2013/03/14. 10.4161/onci.22337

  • CrossRef
  • Google Scholar

• 24

  Fang F. Xiao W. Tian Z. (2018). Challenges of nk cell-based immunotherapy in the new era. Front. Med.12 (4), 440–450. Epub 2018/07/27. 10.1007/s11684-018-0653-9

  • CrossRef
  • Google Scholar

• 25

  Fang F. Xie S. Chen M. Li Y. Yue J. Ma J. et al (2022). Advances in nk cell production. Cell Mol. Immunol.19 (4), 460–481. Epub 2022/01/06. 10.1038/s41423-021-00808-3

  • CrossRef
  • Google Scholar

• 26

  Farcas M. Inngjerdingen M. (2020). Natural killer cell-derived extracellular vesicles in cancer therapy. Scand. J. Immunol.92 (4), e12938. 10.1111/sji.12938

  • CrossRef
  • Google Scholar

• 27

  Federici C. Shahaj E. Cecchetti S. Camerini S. Casella M. Iessi E. et al (2020). Natural-killer-derived extracellular vesicles: Immune sensors and interactors. Front. Immunol.11, 262. 10.3389/fimmu.2020.00262

  • CrossRef
  • Google Scholar

• 28

  Fernandez-Messina L. Rodriguez-Galan A. de Yebenes V. G. Gutierrez-Vazquez C. Tenreiro S. Seabra M. C. et al (2020). Transfer of extracellular vesicle-microrna controls germinal center reaction and antibody production. EMBO Rep.21 (4), e48925. Epub 2020/02/20. 10.15252/embr.201948925

  • CrossRef
  • Google Scholar

• 29

  Fu W. Lei C. Liu S. Cui Y. Wang C. Qian K. et al (2019). Car exosomes derived from effector car-T cells have potent antitumour effects and low toxicity. Nat. Commun.10 (1), 4355. Epub 2019/09/27. 10.1038/s41467-019-12321-3

  • CrossRef
  • Google Scholar

• 30

  Goldenson B. H. Kaufman D. S. (2021). Into the multiverse of gene edited nk cell-based therapeutic strategies. Cell Stem Cell28 (12), 2041–2043. Epub 2021/12/04. 10.1016/j.stem.2021.11.004

  • CrossRef
  • Google Scholar

• 31

  Gong J. H. Maki G. Klingemann H. G. (1994). Characterization of a human cell line (Nk-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia8 (4), 652–658. Epub 1994/04/01.

  • Google Scholar

• 32

  Gorgens A. Corso G. Hagey D. W. Jawad Wiklander R. Gustafsson M. O. Felldin U. et al (2022). Identification of storage conditions stabilizing extracellular vesicles preparations. J. Extracell. Vesicles11 (6), e12238. Epub 2022/06/19. 10.1002/jev2.12238

  • CrossRef
  • Google Scholar

• 33

  Groot Kormelink T. Mol S. de Jong E. C. Wauben M. H. M. (2018). The role of extracellular vesicles when innate meets adaptive. Semin. Immunopathol.40 (5), 439–452. Epub 2018/04/05. 10.1007/s00281-018-0681-1

  • CrossRef
  • Google Scholar

• 34

  Gudbergsson J. M. Jonsson K. Simonsen J. B. Johnsen K. B. (2019). Systematic review of targeted extracellular vesicles for drug delivery - considerations on methodological and biological heterogeneity. J. Control Release306, 108–120. Epub 2019/06/09. 10.1016/j.jconrel.2019.06.006

  • CrossRef
  • Google Scholar

• 35

  Guo J. Wu C. Lin X. Zhou J. Zhang J. Zheng W. et al (2021). Establishment of a simplified dichotomic size-exclusion chromatography for isolating extracellular vesicles toward clinical applications. J. Extracell. Vesicles10 (11), e12145. Epub 2021/09/14. 10.1002/jev2.12145

  • CrossRef
  • Google Scholar

• 36

  Han D. Wang K. Zhang T. Gao G. C. Xu H. (2020). Natural killer cell-derived exosome-entrapped paclitaxel can enhance its anti-tumor effect. Eur. Rev. Med. Pharmacol. Sci.24 (10), 5703–5713. Epub 2020/06/05. 10.26355/eurrev_202005_21362

  • CrossRef
  • Google Scholar

• 37

  Heinemann M. L. Vykoukal J. (2017). Sequential filtration: A gentle method for the isolation of functional extracellular vesicles. Methods Mol. Biol.1660, 33–41. Epub 2017/08/23. 10.1007/978-1-4939-7253-1_4

  • CrossRef
  • Google Scholar

• 38

  Hong Y. Kim I-S. (2022). The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer. Bmb Rep.55 (1), 39–47. 10.5483/BMBRep.2022.55.1.075

  • CrossRef
  • Google Scholar

• 39

  Jaiswal S. Jamieson C. H. Pang W. W. Park C. Y. Chao M. P. Majeti R. et al (2009). Cd47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell138 (2), 271–285. Epub 2009/07/28. 10.1016/j.cell.2009.05.046

  • CrossRef
  • Google Scholar

• 40

  Jia R. Cui K. Li Z. Gao Y. Zhang B. Wang Z. et al (2020). Nk cell-derived exosomes improved lung injury in mouse model of Pseudomonas aeruginosa lung infection. J. Physiol. Sci.70 (1), 50. Epub 2020/10/25. 10.1186/s12576-020-00776-9

  • CrossRef
  • Google Scholar

• 41

  Jiang Y. Jiang H. Wang K. Liu C. Man X. Fu Q. (2021). Hypoxia enhances the production and antitumor effect of exosomes derived from natural killer cells. Ann. Transl. Med.9 (6), 473. 10.21037/atm-21-347

  • CrossRef
  • Google Scholar

• 42

  Jong A. Y. Wu C. H. Li J. Sun J. Fabbri M. Wayne A. S. et al (2017). Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J. Extracell. Vesicles6 (1), 1294368. Epub 2017/03/23. 10.1080/20013078.2017.1294368

  • CrossRef
  • Google Scholar

• 43

  Kaban K. Hinterleitner C. Zhou Y. Salva E. Kantarci A. G. Salih H. R. et al (2021). Therapeutic silencing of bcl-2 using nk cell-derived exosomes as a novel therapeutic approach in breast cancer. Cancers (Basel)13 (10), 2397. Epub 2021/06/03. 10.3390/cancers13102397

  • CrossRef
  • Google Scholar

• 44

  Kang Y. T. Niu Z. Hadlock T. Purcell E. Lo T. W. Zeinali M. et al (2021). On-chip biogenesis of circulating nk cell-derived exosomes in non-small cell lung cancer exhibits antitumoral activity. Adv. Sci. (Weinh)8 (6), 2003747. Epub 2021/03/23. 10.1002/advs.202003747

  • CrossRef
  • Google Scholar

• 45

  Kim H. Y. Min H. K. Song H. W. Yoo A. Lee S. Kim K. P. et al (2022). Delivery of human natural killer cell-derived exosomes for liver cancer therapy: An in vivo study in subcutaneous and orthotopic animal models. Drug Deliv.29 (1), 2897–2911. Epub 2022/09/08. 10.1080/10717544.2022.2118898

  • CrossRef
  • Google Scholar

• 46

  Konoshenko M. Y. Lekchnov E. A. Vlassov A. V. Laktionov P. P. (2018). Isolation of extracellular vesicles: General methodologies and latest trends. Biomed. Res. Int.2018, 1–27. Epub 2018/04/18. 10.1155/2018/8545347

  • CrossRef
  • Google Scholar

• 47

  Korenevskii A. V. Milyutina Y. P. Zhdanova A. A. Pyatygina K. M. Sokolov D. I. Sel'kov S. A. (2018). Mass-spectrometric analysis of proteome of microvesicles produced by nk-92 natural killer cells. Bull. Exp. Biol. Med.165 (4), 564–571. Epub 2018/08/20. 10.1007/s10517-018-4214-7

  • CrossRef
  • Google Scholar

• 48

  Kundu S. Gurney M. O'Dwyer M. (2021). Generating natural killer cells for adoptive transfer: Expanding horizons. Cytotherapy23 (7), 559–566. Epub 2021/01/13. 10.1016/j.jcyt.2020.12.002

  • CrossRef
  • Google Scholar

• 49

  Kusuma G. D. Barabadi M. Tan J. L. Morton D. A. V. Frith J. E. Lim R. (2018). To protect and to preserve: Novel preservation strategies for extracellular vesicles. Front. Pharmacol.9, 1199. Epub 2018/11/14. 10.3389/fphar.2018.01199

  • CrossRef
  • Google Scholar

• 50

  Langevin S. M. Kuhnell D. Orr-Asman M. A. Biesiada J. Zhang X. Medvedovic M. et al (2019). Balancing yield, purity and practicality: A modified differential ultracentrifugation protocol for efficient isolation of small extracellular vesicles from human serum. RNA Biol.16 (1), 5–12. Epub 2019/01/04. 10.1080/15476286.2018.1564465

  • CrossRef
  • Google Scholar

• 51

  Laskowski T. J. Biederstadt A. Rezvani K. (2022). Natural killer cells in antitumour adoptive cell immunotherapy. Epub 2022/07/26. 10.1038/s41568-022-00491-0

  • CrossRef
  • Google Scholar

• 52

  Lavrik I. N. Krammer P. H. (2012). Regulation of Cd95/fas signaling at the disc. Cell Death Differ.19 (1), 36–41. Epub 2011/11/15. 10.1038/cdd.2011.155

  • CrossRef
  • Google Scholar

• 53

  Lee H. Kang H. Kang M. Han C. Yi J. Kwon Y. et al (2020). Heterogeneous subcellular origin of exosome-mimetic nanovesicles engineered from cells. ACS Biomater. Sci. Eng.6 (11), 6063–6068. Epub 2021/01/16. 10.1021/acsbiomaterials.0c01157

  • CrossRef
  • Google Scholar

• 54

  Leon D. L. Fellay I. Mantel P. Y. Walch M. (2017). Killing bacteria with cytotoxic effector proteins of human killer immune cells: Granzymes, granulysin, and perforin. Methods Mol. Biol.1535, 275–284. Epub 2016/12/04. 10.1007/978-1-4939-6673-8_18

  • CrossRef
  • Google Scholar

• 55

  Li D. Wang Y. Jin X. Hu D. Xia C. Xu H. et al (2020). Nk cell-derived exosomes carry mir-207 and alleviate depression-like symptoms in mice. J. Neuroinflammation17 (1), 126. 10.1186/s12974-020-01787-4

  • CrossRef
  • Google Scholar

• 56

  Li P. Kaslan M. Lee S. H. Yao J. Gao Z. (2017). Progress in exosome isolation techniques. Theranostics7 (3), 789–804. Epub 2017/03/04. 10.7150/thno.18133

  • CrossRef
  • Google Scholar

• 57

  Li Y. Hermanson D. L. Moriarity B. S. Kaufman D. S. (2018). Human ipsc-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell23 (2), 181–192.e5. Epub 2018/08/08. 10.1016/j.stem.2018.06.002

  • CrossRef
  • Google Scholar

• 58

  Lian G. Mak T. S. Yu X. Lan H. Y. (2021). Challenges and recent advances in nk cell-targeted immunotherapies in solid tumors. Int. J. Mol. Sci.23 (1), 164. Epub 2022/01/12. 10.3390/ijms23010164

  • CrossRef
  • Google Scholar

• 59

  Lieberman J. (2010). Granzyme a activates another way to die. Immunol. Rev.235 (1), 93–104. Epub 2010/06/12. 10.1111/j.0105-2896.2010.00902.x

  • CrossRef
  • Google Scholar

• 60

  Liu S. Galat V. Galat Y. Lee Y. K. A. Wainwright D. Wu J. (2021). Nk cell-based cancer immunotherapy: From basic biology to clinical development. J. Hematol. Oncol.14 (1), 7. Epub 2021/01/08. 10.1186/s13045-020-01014-w

  • CrossRef
  • Google Scholar

• 61

  Liu W. Li L. Rong Y. Qian D. Chen J. Zhou Z. et al (2020). Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of mir-126. Acta Biomater.103, 196–212. Epub 2019/12/21. 10.1016/j.actbio.2019.12.020

  • CrossRef
  • Google Scholar

• 62

  Lugini L. Cecchetti S. Huber V. Luciani F. Macchia G. Spadaro F. et al (2012). Immune surveillance properties of human nk cell-derived exosomes. J. Immunol.189 (6), 2833–2842. Epub 2012/08/21. 10.4049/jimmunol.1101988

  • CrossRef
  • Google Scholar

• 63

  Ma C. Jiang F. Ma Y. Wang J. Li H. Zhang J. (2019). Isolation and detection technologies of extracellular vesicles and application on cancer diagnostic. Dose Response17 (4), 155932581989100. Epub 2019/12/17. 10.1177/1559325819891004

  • CrossRef
  • Google Scholar

• 64

  MacDonald G. Shi L. Vande Velde C. Lieberman J. Greenberg A. H. (1999). Mitochondria-dependent and -independent regulation of granzyme B-induced apoptosis. J. Exp. Med.189 (1), 131–144. Epub 1999/01/05. 10.1084/jem.189.1.131

  • CrossRef
  • Google Scholar

• 65

  Markova K. Mikhailova V. Milyutina Y. Korenevsky A. Sirotskaya A. Rodygina V. et al (2021). Effects of microvesicles derived from nk cells stimulated with il-1 beta on the phenotype and functional activity of endothelial cells. Int. J. Mol. Sci.22 (24), 13663. 10.3390/ijms222413663

  • CrossRef
  • Google Scholar

• 66

  Mendt M. Kamerkar S. Sugimoto H. McAndrews K. M. Wu C. C. Gagea M. et al (2018). Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight3 (8), e99263. Epub 2018/04/20. 10.1172/jci.insight.99263

  • CrossRef
  • Google Scholar

• 67

  Neviani P. Wise P. M. Murtadha M. Liu C. W. Wu C. H. Jong A. Y. et al (2019). Natural killer-derived exosomal mir-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res.79 (6), 1151–1164. Epub 2018/12/14. 10.1158/0008-5472.CAN-18-0779

  • CrossRef
  • Google Scholar

• 68

  Nie W. Fan W. Jiang A. Wu G. Liu H. Huang L-L. et al (2021). Natural killer cell-derived extracellular vesicle significantly enhanced adoptive T cell therapy against solid tumors via versatilely immunomodulatory coordination. Sci. China-Chemistry64 (11), 1999–2009. 10.1007/s11426-021-1085-8

  • CrossRef
  • Google Scholar

• 69

  Oh S. Lee J. H. Kwack K. Choi S. W. (2019). Natural killer cell therapy: A new treatment paradigm for solid tumors. Cancers (Basel)11 (10), 1534. Epub 2019/10/17. 10.3390/cancers11101534

  • CrossRef
  • Google Scholar

• 70

  Ou Y. H. Zou S. Goh W. J. Wang J. W. Wacker M. Czarny B. et al (2021). Cell-derived nanovesicles as exosome-mimetics for drug delivery purposes: Uses and recommendations. Methods Mol. Biol.2211, 147–170. Epub 2020/12/19. 10.1007/978-1-0716-0943-9_11

  • CrossRef
  • Google Scholar

• 71

  Parolini I. Federici C. Raggi C. Lugini L. Palleschi S. De Milito A. et al (2009). Microenvironmental Ph is a key factor for exosome traffic in tumor cells. J. Biol. Chem.284 (49), 34211–34222. Epub 2009/10/06. 10.1074/jbc.M109.041152

  • CrossRef
  • Google Scholar

• 72

  Patel G. K. Khan M. A. Zubair H. Srivastava S. K. Khushman M. Singh S. et al (2019). Comparative analysis of exosome isolation methods using culture supernatant for optimum yield, purity and downstream applications. Sci. Rep.9 (1), 5335. Epub 2019/03/31. 10.1038/s41598-019-41800-2

  • CrossRef
  • Google Scholar

• 73

  Pitchaimani A. Nguyen T. D. T. Aryal S. (2018). Natural killer cell membrane infused biomimetic liposomes for targeted tumor therapy. Biomaterials160, 124–137. Epub 2018/02/07. 10.1016/j.biomaterials.2018.01.018

  • CrossRef
  • Google Scholar

• 74

  Rafei H. Daher M. Rezvani K. (2021). Chimeric antigen receptor (car) natural killer (Nk)-Cell therapy: Leveraging the power of innate immunity. Br. J. Haematol.193 (2), 216–230. Epub 2020/11/21. 10.1111/bjh.17186

  • CrossRef
  • Google Scholar

• 75

  Richter M. Vader P. Fuhrmann G. (2021). Approaches to surface engineering of extracellular vesicles. Adv. Drug Deliv. Rev.173, 416–426. Epub 2021/04/09. 10.1016/j.addr.2021.03.020

  • CrossRef
  • Google Scholar

• 76

  Sakamoto N. Ishikawa T. Kokura S. Okayama T. Oka K. Ideno M. et al (2015). Phase I clinical trial of autologous nk cell therapy using novel expansion method in patients with advanced digestive cancer. J. Transl. Med.13, 277. Epub 2015/08/26. 10.1186/s12967-015-0632-8

  • CrossRef
  • Google Scholar

• 77

  Sayitoglu E. C. Georgoudaki A. M. Chrobok M. Ozkazanc D. Josey B. J. Arif M. et al (2020). Boosting natural killer cell-mediated targeting of sarcoma through dnam-1 and Nkg2d. Front. Immunol.11, 40. Epub 2020/02/23. 10.3389/fimmu.2020.00040

  • CrossRef
  • Google Scholar

• 78

  Shah N. N. Baird K. Delbrook C. P. Fleisher T. A. Kohler M. E. Rampertaap S. et al (2015). Acute gvhd in patients receiving il-15/4-1bbl activated nk cells following T-cell-depleted stem cell transplantation. Blood125 (5), 784–792. Epub 2014/12/03. 10.1182/blood-2014-07-592881

  • CrossRef
  • Google Scholar

• 79

  Shen M. Ren X. (2018). New insights into the biological impacts of immune cell-derived exosomes within the tumor environment. Cancer Lett.431, 115–122. 10.1016/j.canlet.2018.05.040

  • CrossRef
  • Google Scholar

• 80

  Shoae-Hassani A. Hamidieh A. A. Behfar M. Mohseni R. Mortazavi-Tabatabaei S. A. Asgharzadeh S. (2017). Nk cell-derived exosomes from nk cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated nk cells. J. Immunother.40 (7), 265–276. Epub 2017/06/18. 10.1097/CJI.0000000000000179

  • CrossRef
  • Google Scholar

• 81

  Sparrow E. Bodman-Smith M. D. (2020). Granulysin: The attractive side of a natural born killer. Immunol. Lett.217, 126–132. Epub 2019/11/15. 10.1016/j.imlet.2019.11.005

  • CrossRef
  • Google Scholar

• 82

  Sun H. Shi K. Qi K. Kong H. Zhang J. Dai S. et al (2019). Natural killer cell-derived exosomal mir-3607-3p inhibits pancreatic cancer progression by targeting il-26. Front. Immunol.10, 2819. 10.3389/fimmu.2019.02819

  • CrossRef
  • Google Scholar

• 83

  Tang X. Yang L. Li Z. Nalin A. P. Dai H. Xu T. et al (2018). First-in-Man clinical trial of car nk-92 cells: Safety test of Cd33-car nk-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am. J. Cancer Res.8 (6), 1083–1089. Epub 2018/07/24.

  • Google Scholar

• 84

  Thakur A. Parra D. C. Motallebnejad P. Brocchi M. Chen H. J. (2022). Exosomes: Small vesicles with big roles in cancer, vaccine development, and therapeutics. Bioact. Mater10, 281–294. Epub 2021/12/14. 10.1016/j.bioactmat.2021.08.029

  • CrossRef
  • Google Scholar

• 85

  Wahlgren J. De L. K. T. Brisslert M. Vaziri Sani F. Telemo E. Sunnerhagen P. et al (2012). Plasma exosomes can deliver exogenous short interfering rna to monocytes and lymphocytes. Nucleic Acids Res.40 (17), e130. Epub 2012/05/24. 10.1093/nar/gks463

  • CrossRef
  • Google Scholar

• 86

  Wang G. Hu W. Chen H. Shou X. Ye T. Xu Y. (2019). Cocktail strategy based on nk cell-derived exosomes and their biomimetic nanoparticles for dual tumor therapy. Cancers (Basel)11 (10), 1560. Epub 2019/10/17. 10.3390/cancers11101560

  • CrossRef
  • Google Scholar

• 87

  Wang L. Wang Y. Quan J. (2020). Exosomal mir-223 derived from natural killer cells inhibits hepatic stellate cell activation by suppressing autophagy. Mol. Med.26 (1), 81. Epub 2020/09/03. 10.1186/s10020-020-00207-w

  • CrossRef
  • Google Scholar

• 88

  Wang L. Wang Y. Quan J. (2020). Exosomes derived from natural killer cells inhibit hepatic stellate cell activation and liver fibrosis. Hum. Cell33 (3), 582–589. Epub 2020/05/26. 10.1007/s13577-020-00371-5

  • CrossRef
  • Google Scholar

• 89

  Weng J. Xiang X. Ding L. Wong A. L. Zeng Q. Sethi G. et al (2021). Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?Semin. Cancer Biol.74, 105–120. Epub 2021/05/15. 10.1016/j.semcancer.2021.05.011

  • CrossRef
  • Google Scholar

• 90

  Whitford W. Guterstam P. (2019). Exosome manufacturing status. Future Med. Chem.11 (10), 1225–1236. Epub 2019/07/10. 10.4155/fmc-2018-0417

  • CrossRef
  • Google Scholar

• 91

  Wu C-H. Li J. Li L. Sun J. Fabbri M. Wayne A. S. et al (2019). Extracellular vesicles derived from natural killer cells use multiple cytotoxic proteins and killing mechanisms to target cancer cells. J. Extracell. Vesicles8 (1), 1588538. 10.1080/20013078.2019.1588538

  • CrossRef
  • Google Scholar

• 92

  Wu Y. Deng W. Klinke D. J. (2015). Exosomes: Improved methods to characterize their morphology, RNA content, and surface protein biomarkers. Analyst140 (19), 6631–6642. Epub 2015/09/04. 10.1039/c5an00688k

  • CrossRef
  • Google Scholar

• 93

  Yang D. Zhang W. Zhang H. Zhang F. Chen L. Ma L. et al (2020). Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics10 (8), 3684–3707. Epub 2020/03/25. 10.7150/thno.41580

  • CrossRef
  • Google Scholar

• 94

  Yang P. Cao X. Cai H. Feng P. Chen X. Zhu Y. et al (2021). The exosomes derived from car-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol.360, 104262. Epub 2020/12/30. 10.1016/j.cellimm.2020.104262

  • CrossRef
  • Google Scholar

• 95

  Yang P. Peng Y. Feng Y. Xu Z. Feng P. Cao J. et al (2021). Immune cell-derived extracellular vesicles - new strategies in cancer immunotherapy. Front. Immunol.12, 771551. 10.3389/fimmu.2021.771551

  • CrossRef
  • Google Scholar

• 96

  Yu L. L. Zhu J. Liu J. X. Jiang F. Ni W. K. Qu L. S. et al (2018). A comparison of traditional and novel methods for the separation of exosomes from human samples. Biomed. Res. Int.2018, 1–9. Epub 2018/08/28. 10.1155/2018/3634563

  • CrossRef
  • Google Scholar

• 97

  Yu S. Kim V. N. (2020). A tale of non-canonical tails: Gene regulation by post-transcriptional rna tailing. Nat. Rev. Mol. Cell Biol.21 (9), 542–556. Epub 2020/06/03. 10.1038/s41580-020-0246-8

  • CrossRef
  • Google Scholar

• 98

  Zhang L. Y. Yang X. Wang S. B. Chen H. Pan H. Y. Hu Z. M. (2020). Membrane derived vesicles as biomimetic carriers for targeted drug delivery system. Curr. Top. Med. Chem.20 (27), 2472–2492. Epub 2020/09/24. 10.2174/1568026620666200922113054

  • CrossRef
  • Google Scholar

• 99

  Zhang M. Shao W. Yang T. Liu H. Guo S. Zhao D. et al (2022). Conscription of immune cells by light-activatable silencing nk-derived exosome (lasneo) for synergetic tumor eradication. Adv. Sci. (Weinh)9, e2201135. Epub 2022/06/07. 10.1002/advs.202201135

  • CrossRef
  • Google Scholar

• 100

  Zhang Y. Bi J. Huang J. Tang Y. Du S. Li P. (2020). Exosome: A review of its classification, isolation techniques, storage, diagnostic and targeted therapy Applications&lt. Int. J. Nanomedicine15, 6917–6934. Epub 2020/10/17. 10.2147/IJN.S264498

  • CrossRef
  • Google Scholar

• 101

  Zhang Y. Chopp M. Zhang Z. G. Katakowski M. Xin H. Qu C. et al (2017). Systemic administration of cell-free exosomes generated by human bone marrow derived mesenchymal stem cells cultured under 2d and 3d conditions improves functional recovery in rats after traumatic brain injury. Neurochem. Int.111, 69–81. Epub 2016/08/20. 10.1016/j.neuint.2016.08.003

  • CrossRef
  • Google Scholar

• 102

  Zhu L. Gangadaran P. Kalimuthu S. Oh J. M. Baek S. H. Jeong S. Y. et al (2018). Novel alternatives to extracellular vesicle-based immunotherapy - exosome mimetics derived from natural killer cells. Artif. Cells Nanomed Biotechnol.46 (3), S166–S179. Epub 2018/08/10. 10.1080/21691401.2018.1489824

  • CrossRef
  • Google Scholar

• 103

  Zhu L. Kalimuthu S. Gangadaran P. Oh J. M. Lee H. W. Baek S. H. et al (2017). Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics7 (10), 2732–2745. Epub 2017/08/19. 10.7150/thno.18752

  • CrossRef
  • Google Scholar

• 104

  Zhu L. Kalimuthu S. Oh J. M. Gangadaran P. Baek S. H. Jeong S. Y. et al (2019). Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by il-15 priming. Biomaterials190-191, 38–50. Epub 2018/11/06. 10.1016/j.biomaterials.2018.10.034

  • CrossRef
  • Google Scholar